Printer Friendly

Patients with persistent atrial fibrillation.

PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION who received dronedarone (Multaq[R]) in a controlled trial experienced a high risk of death, stroke, and hospitalization for heart failure. The trial was halted when it was discovered that this risk had developed. The Food and Drug Administration (F.D.A.) intended to review the data from the trial. For now, patients taking dronedarone for nonpermanent atrial fibrillation should continue to take it, but this medication should not be newly prescribed to patients with permanent atrial fibrillation.

This medication is approved to treat paroxysmal atrial fibrillation (intermittent), persistent atrial fibrillation, or atrial flutter. It was approved by the F.D.A. in 2009 after the ATHENA clinical trial showed that it decreased deaths in patients with non-permanent atrial fibrillation and atrial flutter.

(Source: F.D.A. MedWatch Alert, August 2011.)
COPYRIGHT 2011 Vegetus Publications
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:POSTSCRIPTS
Publication:Nutrition Health Review
Date:Jun 22, 2011
Words:136
Previous Article:American Academy of Pediatrics' circumcision policy.
Next Article:Adverse drug events such as esophagitis.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |